Thermo Fisher Scientific Inc. (BVMF:TMOS34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 841.63B -6.8% |
| Revenue (ttm) | 236.88B +5.4% |
| Net Income | 35.89B +5.1% |
| EPS | 95.35 +6.7% |
| Shares Out | n/a |
| PE Ratio | 23.45 |
| Forward PE | 17.55 |
| Dividend | 0.13 (0.29%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 336 |
| Average Volume | 7,227 |
| Open | 45.75 |
| Previous Close | 46.64 |
| Day's Range | 45.75 - 46.07 |
| 52-Week Range | 44.33 - 71.97 |
| Beta | 0.88 |
| RSI | 34.24 |
| Earnings Date | Apr 23, 2026 |
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and... [Read more]
Financial Performance
In 2025, Thermo Fisher Scientific's revenue was $44.56 billion, an increase of 3.91% compared to the previous year's $42.88 billion. Earnings were $6.70 billion, an increase of 5.82%.
Financial numbers in USD Financial StatementsNews
Thermo Fisher Scientific's PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the opening of a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, locat...
Amazon among seven added to Jefferies’ Franchise Picks list
Jefferies analysts added Amazon.com (AMZN), AppLovin (APP), Credo Technology (CRDO), McDonald’s (MCD), RadNet (RDNT), Thermo Fisher (TMO) and UL Solutions (ULS) to Jefferies’ Franchise Picks list, whi...
Thermo Fisher resumed with a Sector Perform at RBC Capital
RBC Capital resumed coverage of Thermo Fisher (TMO) with a Sector Perform rating and $490 price target The rating balances confidence in end market improvement with the structural risks to…
Nuvation Bio collaborating with Thermo Fisher to manufacture Ibtrozi in NSCLC
Nuvation Bio (NUVB) announced the completion of process tech transfer and product introduction to Thermo Fisher (TMO) for Ibtrozi – taletrectinib – to treat advanced or metastatic ROS1-positive non-sm...
Nalgene Outdoor Introduces Fresh Flow™ Straw Bottle
ROCHESTER, N.Y.--(BUSINESS WIRE)--Nalgene Outdoor today introduces the Fresh Flow™ straw bottle, a new addition to its reusable bottle collection designed to give fans more ways to hydrate without sac...
Thermo Fisher Scientific Proxy statement: Proxy filing
Thermo Fisher Scientific filed a proxy statement on May 11, 2026, providing details for shareholder voting and corporate governance matters.
Thermo Fisher Scientific's Clinical Research Business Named a Leader Among CROs in 2026 ISG Provider Lens™ Report for Use of AI in Clinical Trials
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, earned a Leader designation among contract research organizations (CROs) in the 2026 ISG Provider L...
Thermo Fisher Scientific Unveils an Integrated Platform to Advance Scalable Cell Therapy Manufacturing
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Gibco™ CTS™ DynaXS™ Single Use Bioreactor, a purpose-built expansion platform ...
Thermo Fisher Scientific Opens U.S. Flagship Bioprocess Design Center to Accelerate the Delivery of Life-changing Therapies
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the opening of its flagship U.S. Bioprocess Design Center (BDC) at the company's Pl...
Thermo Fisher Scientific to Host Investor Day
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will hold its 2026 Investor Day on Wednesday, May 20, 2026, starting at 9:00 a.m. ET in...
Thermo Fisher to Sell Microbiology Business to Astorg
Thermo Fisher Scientific has struck a deal to sell its microbiology business to European private-equity firm Astorg for about $1.075 billion.
Thermo Fisher price target lowered to $620 from $670 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh lowered the firm’s price target on Thermo Fisher (TMO) to $620 from $670 and keeps an Overweight rating on the shares. Investors “were clearly looking…
Thermo Fisher to sell microbiology business to Astorg for $1.075B
Thermo Fisher (TMO) Scientific has signed a definitive agreement to sell its microbiology business to Astorg for consideration of approximately $1.075B, consisting of cash and a $50M seller note. The…
Thermo Fisher to sell its microbiology business to Astorg for about $1.08 billion
Thermo Fisher Scientific said on Monday it has agreed to sell its microbiology business to a pan-European private equity firm Astorg for about $1.08 billion, consisting of cash and a $50...
Thermo Fisher Scientific Signs Agreement to Sell its Microbiology Business to Astorg
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has signed a definitive agreement to sell its microbiology busi...
Thermo Fisher price target lowered to $600 from $700 at Stifel
Stifel analyst Daniel Arias lowered the firm’s price target on Thermo Fisher (TMO) to $600 from $700 and keeps a Buy rating on the shares.
Thermo Fisher price target lowered to $639 from $653 at Baird
Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Thermo Fisher (TMO) to $639 from $653 and keeps an Outperform rating on the shares. The firm updated its…
Thermo Fisher sees Q2 EPS $5.69-$5.74, consensus $5.81
Sees Q2 organic revenue growth 3%. Guidance taken from Q1 earnings conference call.
Thermo Fisher raises FY26 adjusted EPS view to $24.64-$25.12 from $24.22-$24.80
Consensus $24.80. Raises FY26 revenue view to $47.3B-$48.1B from $46.3B-$47.2B, consensus $47.7B. Says guidance raise reflects strong start to year and Clario acquisition. Says guidance assumes 3%-4% ...
Thermo Fisher Scientific Earnings Call Transcript: Q1 2026
Q1 saw 6% revenue and adjusted EPS growth, driven by pharma/biotech strength and the Clario acquisition. Full-year guidance was raised for both revenue and EPS, with strong segment performance and ongoing innovation offsetting inflation and macro headwinds.
Thermo Fisher Scientific Earnings release: Q1 2026
Thermo Fisher Scientific released its Q1 2026 earnings on April 23, 2026, summarizing the period's financial results.
Thermo Fisher Scientific Quarterly report: Q1 2026
Thermo Fisher Scientific has published its Q1 2026 quarterly earnings report on April 23, 2026.
Thermo Fisher posts quarterly results beat as lab products, biopharma services grow
Thermo Fisher Scientific on Thursday reported first-quarter profit and revenue above Wall Street estimates, as growth in its laboratory products and biopharma services business helped offset softnes...
Thermo Fisher reports Q1 adjusted EPS $5.44, consensus $5.24
Reports Q1 revenue $11.01B, consensus $10.86B. “We delivered a strong start to the year, reflecting excellent execution by our team, as we leveraged the PPI Business System to drive operational…
Thermo Fisher Scientific Reports First Quarter 2026 Results
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 28, 2026. First ...